Introduction {#H1-1-ZOI180084}
============

Nineteen percent of the US population overall, and of the US population with cancer in particular, are from rural areas.^[@zoi180084r1],[@zoi180084r2]^ Rural patients with cancer have been shown to have worse outcomes than their urban counterparts. A major recent report indicated that the age-adjusted rate of cancer deaths in rural areas from 2011 to 2015 was 180.4 per 100 000 individuals, compared with just 157.8 per 100 000 individuals in large metropolitan areas.^[@zoi180084r2]^ Thought leaders have expressed concerns that these differences might be attributed to rural individuals' reduced access to medical, technological, and financial resources, as well as adverse health status and shortened life spans.^[@zoi180084r3]^ The Cancer Moonshot initiative emphasized that rural patients with cancer experience disproportionate morbidity and mortality and indicated the importance of increased research into disparities between rural and urban patients.^[@zoi180084r4]^ Indeed, disparities in cancer outcomes for rural patients in the United States may actually be increasing rather than decreasing.^[@zoi180084r2]^ Whether this disparity is due to inadequate access to quality cancer care or other characteristics of patients residing in rural areas, such as different clinical, demographic, or disease profiles, is unclear.

In this context, an important question is whether rural and urban patients with cancer who receive similar care have similar outcomes. To address this, we compared survival outcomes between patients with cancer from rural vs urban locales who participated in therapeutic clinical trials. Patients receiving care in this setting are uniformly staged, treated, and followed up under protocol-specific guidelines, reducing the potential influences of inconsistent pretreatment evaluation, care, and posttreatment surveillance. If outcomes between rural and urban patients with cancer in clinical trials are similar, then access to uniform treatment strategies of the type represented by clinical trial care could help alleviate disparities in outcomes.

Methods {#H1-2-ZOI180084}
=======

Patients {#H2-1-ZOI180084}
--------

Data were derived from patient medical records for trial participants enrolled between January 1, 1986, and December 31, 2012, to clinical treatment trials conducted by SWOG (formerly the Southwest Oncology Group), a National Clinical Trials Network and Community Oncology Research Program group sponsored by the National Cancer Institute (NCI). Only data from phase 3 or large phase 2/3 trials for which the primary analysis was previously published were included. The following cancer types were included: acute myeloid leukemia, brain, breast, colorectal, lung, lymphoma, myeloma, ovarian, prostate, and sarcoma (gastrointestinal stromal tumors). We combined trials with similar histology and stage to increase our power to identify potential differences in survival outcomes between rural and urban patients. In the case of advanced prostate cancer, we analyzed SWOG trials S8894 and S9346 separately, because each of these trials enrolled more than 1000 patients. Each trial included in this analysis was previously approved by an institutional review board; informed consent was previously obtained from all patients for each study included. Institutional review board approval and informed consent of study participants for this comparative effectiveness study was not required because secondary data that were not identifiable were used. The research question and analysis plan were defined prospectively in accordance with the International Society for Pharmacoeconomics and Outcomes Research ([ISPOR](http://www.equator-network.org/reporting-guidelines/good-research-practices-for-comparative-effectiveness-research-defining-reporting-and-interpreting-nonrandomized-studies-of-treatment-effects-using-secondary-data-sources-the-ispor-good-research-pr/)) reporting guideline^[@zoi180084r5]^ for the conduct of comparative effectiveness studies.

Covariates and Outcome Variables {#H2-2-ZOI180084}
--------------------------------

We defined rural residence using 2003 Rural-Urban Continuum Codes (RUCCs) developed by the Economic Research Service of the US Department of Agriculture (eTable in the [Supplement](#note-ZOI180084-1-s){ref-type="supplementary-material"}).^[@zoi180084r6]^ We matched RUCCs with patient zip codes using 2010 United States Postal Service Zip Code Crosswalk Files from the US Department of Housing and Urban Development.^[@zoi180084r7]^ Guided by recent studies in the literature, our primary analysis used a prespecified cut point, dividing the 9 RUCCs into 2 categories: urban (RUCCs 1-3) vs rural (RUCCs 4-9).^[@zoi180084r8],[@zoi180084r9],[@zoi180084r10]^

Each analysis adjusted for the demographic variables age (\<65 years vs ≥65 years), self-reported race (black vs other), and sex (where appropriate), which could potentially influence the relationship between residency status and survival outcomes. In addition, each analysis adjusted for important disease-specific clinical adjustment variables. Only clinical adjustment variables with a known effect on survival that were measured in all studies within an analysis were included (see [Table 1](#zoi180084t1){ref-type="table"} for clinical adjustment variables). These variables often represented those factors used to balance randomization assignment (ie, stratification factors).

###### Study Descriptions

  Type of Cancer                                    Trials by Study No.                               Enrollment Date Range   Major Eligibility Criteria                                                                                                                Clinical Prognostic Factors[^a^](#zoi180084t1n1){ref-type="table-fn"}                                                                                     Rural/Total Sample, No. (%)
  ------------------------------------------------- ------------------------------------------------- ----------------------- ----------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------
  Brain                                             S8737, S0001                                      1988-2005               No prior chemotherapy; performance status ≤2                                                                                              Prior surgery: biopsy only vs resection; performance status: 0-1 vs \>1                                                                                   74/323 (22.9)
  Breast, adjuvant ER-negative and PR-negative      S8897, S9313, S9623, S0012, S0221, S0307          1989-2012               Early stage (I-III); no prior chemotherapy for this breast cancer (for S0307, chemotherapy allowed concurrent with registration)          No. of positive lymph nodes: ≥4 vs \<4; tumor size: ≤5 cm vs \>5 cm; premenopausal vs postmenopausal                                                      875/5026 (17.4)
  Breast, adjuvant ER-positive and/or PR-positive   S8814, S8897, S9313, S9623, S0012, S0221, S0307   1989-2012               Early stage (I-III); no prior chemotherapy for this breast cancer (for S0307, chemotherapy allowed concurrent with registration)          No. of positive lymph nodes: ≥4 vs \<4; tumor size: ≤5 cm vs \>5 cm; premenopausal vs postmenopausal                                                      1977/11 413 (17.3)
  Breast, advanced                                  S0226, S0500                                      2004-2012               Stage IV; no prior chemotherapy for metastatic disease                                                                                    *ERBB2* (formerly *HER2*)--negative vs *ERBB2*-positive; premenopausal vs postmenopausal; ER-positive and/or PR-positive vs ER-negative and PR-negative   244/1247 (19.6)
  Colorectal, advanced                              S8611, S8905, S9420                               1987-1999               Metastatic (disseminated); maximum 1 prior adjuvant chemotherapy or immunotherapy                                                         Performance status: 0-1 vs 2                                                                                                                              286/1431 (20.0)
  Gastric, adjuvant                                 S9008                                             1991-1998               Stages IB-IV (M0)                                                                                                                         No. of involved lymph nodes: 0 vs 1-3 vs ≥4; T stage: T1-T2 vs T3-T4                                                                                      83/488 (17.0)
  Colorectal, adjuvant                              S9304, S9415                                      1994-2000               Stage M0; no prior systemic or radiation therapy                                                                                          No. of nodes involved: N0 vs N1 vs N2-N3; performance status: 0-1 vs 2; invasion of perirectal fat or adjacent organs: T1-T2 vs T3-T4                     605/2593 (23.3)
  Prostate 1, advanced                              S8894                                             1989-1994               D2 disease                                                                                                                                Performance status: \<2 vs ≥2; severity of disease: minimal vs extensive                                                                                  304/1333 (22.8)
  Prostate 2, advanced                              S9346                                             1995-2008               D2 disease                                                                                                                                Performance status: \<2 vs ≥2; severity of disease: minimal vs extensive                                                                                  320/2055 (15.6)
  Prostate, advanced hormone refractory             S9916, S0421                                      1999-2010               Metastatic prostate cancer that is unresponsive or refractory to hormone therapy; maximum 1 prior systemic therapy                        Extraskeletal metastatic disease: yes vs no; PSA progression only: yes vs no; performance status: \<2 vs ≥2                                               325/1658 (19.6)
  Ovarian, advanced                                 S8501, S8790, S9701                               1986-2001               Stage III or IV                                                                                                                           Disease: optimal stage III vs suboptimal stage III or stage IV[^b^](#zoi180084t1n2){ref-type="table-fn"}                                                  170/903 (18.8)
  Acute myeloid leukemia                            S8600, S8706, S9031, S9333, S0106                 1986-2009               No previous systemic chemotherapy for acute leukemia                                                                                      SWOG performance status: \<2 vs ≥2                                                                                                                        455/1748 (26.0)
  NSCLC, advanced                                   S8738, S9308, S9509, S0003                        1988-2002               No previous systemic chemotherapy or biologic therapy for NSCLC                                                                           Weight loss: \<5% vs ≥5%; LDH: normal (≤ULN) vs abnormal (\>ULN); stage of disease: IIIB vs IV                                                            304/1461 (20.8)
  Non-Hodgkin lymphoma, advanced aggressive         S8516, S9704                                      1986-2007               Intermediate or high-grade histology; no prior chemotherapy or radiation therapy for lymphoma[^c^](#zoi180084t1n3){ref-type="table-fn"}   IPI risk: low vs low-intermediate vs high-intermediate vs high                                                                                            278/1155 (24.1)
  Non-Hodgkin lymphoma, advanced indolent           S0016, S8809                                      1988-2008               Stages IIB-IV; no prior chemotherapy or radiation therapy for lymphoma                                                                    IPI risk: low vs low-intermediate vs high-intermediate vs high                                                                                            209/1035 (20.2)
  Myeloma, multiple                                 S8624, S9028, S9210, S9321, S0232, S0777          1987-2012               No prior chemotherapy for this disease                                                                                                    Stage: I-II vs III                                                                                                                                        568/2493 (22.8)
  Gastrointestinal stromal tumor, advanced          S0033                                             2000-2001               Metastatic or unresectable                                                                                                                Performance status: 0-2 vs 3; measurable vs nonmeasurable disease                                                                                         107/633 (16.9)
  Total                                             44 unique trials                                  1986-2012                                                                                                                                                                                                                                                                                                                   7184/36 995 (19.4)

Abbreviations: ER, estrogen receptor; IPI, International Prognostic Index; LDH, lactate dehydrogenase; NSCLC, non--small cell lung cancer; PR, progesterone receptor; PSA, prostate-specific antigen; ULN, upper limit of normal.

Including age (\<65 vs ≥65 years), race (black vs other), and sex (where appropriate).

Definitions for suboptimal vs optimal stage III differed by study.

Study S9704 allows a single course of chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without rituximab.

Because men represented a very small fraction of the patients with breast cancer, male patients were excluded from the 3 breast cancer groups, and sex was not included as a covariate in these analyses. Analyses of non-Hodgkin lymphoma did not include age as a separate covariate because age is included in the International Prognostic Index.

The primary outcome was overall survival (OS), measured as days from study registration to death by any cause or, for those patients still alive, as days to last contact (censored). Patients lost to follow-up were also censored at their date of last contact. We also examined progression-free survival (PFS) and cancer-specific survival (CSS) as secondary outcomes. We defined PFS as days from study registration to the date of death by any cause, evidence of protocol-defined relapse or progressive disease, or date of last contact for those alive and progression free (censored). We measured CSS as days from study registration to date of cancer-specific death, death by another cause (censored), or last contact for those alive at last contact (censored). Detailed cause-of-death information was available for 28.0% of patient deaths. For the remaining 72.0%, we considered any death preceded by documented relapse or progression a cancer-specific death. We limited analyses to the first 5 years after registration in our main analysis in order to focus on cancer-related and treatment-related survival. Patients with last contact date or death date greater than 5 years postregistration were censored at 5 years of follow-up. Survival outcomes were grouped by adjuvant (ie, nonmetastatic) vs advanced (ie, metastatic) to identify whether global patterns of outcomes for rural vs urban patients differed by these disease settings.

Statistical Analysis {#H2-3-ZOI180084}
--------------------

To examine observed survival differences by residency status, we generated Kaplan-Meier OS curves for each of the 17 cancer cohorts, separately for rural and urban patients.^[@zoi180084r11]^ We used multivariate Cox regression to estimate the effect of patient residence on survival outcomes while controlling for the major disease-specific prognostic factors and the demographic variables.^[@zoi180084r12]^ Each analysis was stratified by study.

We further explored whether patterns of survival between rural and urban patients might substantively differ for different definitions of rural residency. We used variable cut point analysis to examine the association of residency and OS for each of the 8 possible definitions of rural residency based on the RUCCs.^[@zoi180084r13],[@zoi180084r14]^ Although the primary analysis was based on 5 years of follow-up, for the variable cut point analysis, we allowed follow-up to vary from 1 to 10 years to allow for different prognosis patterns across the panel of 17 cancer types, resulting in 80 separate analyses per cancer type, or 1360 analyses overall. For each analysis, we derived the signed (according to the direction of the effect) χ^2^ statistic for the model-estimated association of rural or urban residence and OS in multivariable Cox regression.^[@zoi180084r12]^ We treated these 17 χ^2^ statistics as independent random variables and used a 1-sample *t* test to assess whether they collectively differed from 0. We then plotted the corresponding signed *z* scores.

Tests for statistical significance were 2-sided, α = .05. Informal (*P* = .01) and formal (per Bonferroni) multiple comparison tests for the variable cut point analysis were provided. Data through January 30, 2018, were examined.

Results {#H1-3-ZOI180084}
=======

Overall, 36 995 patients enrolled between January 1, 1986, and December 31, 2012, in 44 SWOG phase 2/3 or phase 3 trials were analyzed ([Table 1](#zoi180084t1){ref-type="table"}). Of the total study population, 19.4% resided in rural areas, the same as the rural proportion of the US population with cancer. [Figure 1](#zoi180084f1){ref-type="fig"} shows a map of the trial registrations by rural vs urban status. Although all states are represented, the states with the fewest enrollments were Maine (82), Wyoming (93), and Rhode Island (102). Registrations in SWOG trials generally reflect the geographic population patterns of the United States, although with more patients enrolled from the Midwest (39% vs 21%) and fewer from the south (24% vs 37%). Rural patients were well represented within major geographic regions in the United States (West, Midwest, South, and Northeast) ([Figure 1](#zoi180084f1){ref-type="fig"}).

![Map Showing 36 995 SWOG Enrollments From 1986 to 2012 by Rural vs Urban County Origin\
The percentage of total SWOG and US cancer population cases by region are shown in the table, along with the estimated proportion in rural areas for each region.](jamanetwopen-1-e181235-g001){#zoi180084f1}

Patient Characteristics {#H2-4-ZOI180084}
-----------------------

Overall, 27.7% (range across the 17 cohort analyses, 7.8%-74.5%) of patients (10 247 of 36 995) were aged 65 years or older, 40.3% (range across 17 cohort analyses, 28.1%-45.9%; 5381 of 13 360 patients) were female in the non-sex-specific analyses, and 10.8% (range across 17 cohort analyses, 1.9%-22.4%; 4003 of 36 995 patients) were black. [Table 2](#zoi180084t2){ref-type="table"} shows these statistics as well as descriptions of the clinical prognostic factors used in the analyses, both overall and separately by rural and urban residence. Patients residing in rural areas were older on average (rural, 30.7% aged ≥65 years vs urban, 27.0% aged ≥65 years; difference, 3.7%; 95% CI, 2.5%-4.9%; *P *\< .001), were similar with respect to sex (rural, 40.4% female vs urban, 39.7% female; difference, 0.6%; 95% CI, −1.4% to 2.6%; *P *= .53), and were less likely to report being black (rural, 5.4% vs urban, 12.1%; difference, 6.7%; 95% CI, 6.1%-7.3%; *P *\< .001) than patients residing in urban areas. There were very few statistically significant differences between rural and urban patients with respect to clinical prognostic factors.

###### Patient Characteristics

  Cancer Cohort                                         Patients, No. (%)                                                                                                                                                                                                                                                                                                                                                                          
  ----------------------------------------------------- ------------------- ------------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------- ------------------------------------------------------- ------------- --------------------------- ------------- ------------------------------------------------------------------------------- -------------
  **Brain**                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Overall                                               323 (100)           61 (18.9)                                               124 (38.4)                                             6 (1.9)                                                 Performance status \>1                                  69 (21.4)     Prior surgery biopsy only   79 (24.5)     NA                                                                              
  Rural                                                 74 (22.9)           18 (24.3)                                               28 (37.8)                                              1 (1.4)                                                 16 (21.6)                                               18 (24.3)                                                                                                                               
  Urban                                                 249 (77.1)          43 (17.3)                                               96 (38.6)                                              5 (2.0)                                                 53 (21.3)                                               61 (24.5)                                                                                                                               
  **Breast, Adjuvant ER-Negative and PR-Negative**                                                                                                                                                                                                                                                                                                                                                                                                 
  Overall                                               5026 (100)          394 (7.8)                                               NA                                                     655 (13.0)                                              Tumor \>5 cm                                            462 (9.2)     Postmenopausal              2402 (47.8)   ≥4 Nodes[^c^](#zoi180084t2n3){ref-type="table-fn"}                              581 (12.0)
  Rural                                                 875 (17.4)          84 (9.6)[^d^](#zoi180084t2n4){ref-type="table-fn"}      55 (6.3)                                               82 (9.4)                                                442 (50.5)                                              116 (13.6)                                                                                                                              
  Urban                                                 4151 (82.6)         310 (7.5)                                               600 (14.5)[^e^](#zoi180084t2n5){ref-type="table-fn"}   380 (9.2)                                               1960 (47.2)                                             465 (11.6)                                                                                                                              
  **Breast, Adjuvant ER-Positive and/or PR-Positive**                                                                                                                                                                                                                                                                                                                                                                                              
  Overall                                               11413 (100)         1552 (13.6)                                             NA                                                     822 (7.2)                                               Tumor \>5 cm                                            957 (8.4)     Postmenopausal              6458 (56.6)   ≥4 Nodes[^c^](#zoi180084t2n3){ref-type="table-fn"}                              2504 (22.3)
  Rural                                                 1977 (17.3)         333 (16.8)[^e^](#zoi180084t2n5){ref-type="table-fn"}    59 (3.0)                                               162 (8.2)                                               1221 (61.8)[^e^](#zoi180084t2n5){ref-type="table-fn"}   433 (22.3)                                                                                                                              
  Urban                                                 9436 (82.7)         1219 (12.9)                                             763 (8.1)[^e^](#zoi180084t2n5){ref-type="table-fn"}    795 (8.4)                                               5237 (55.5)                                             2071 (22.3)                                                                                                                             
  **Breast, Advanced**                                                                                                                                                                                                                                                                                                                                                                                                                             
  Overall                                               1247 (100)          473 (37.9)                                              NA                                                     146 (11.7)                                              ER-negative and PR-negative                             184 (14.8)    Postmenopausal              1134 (90.9)   *ERBB2* (formerly *HER2*)--negative[^c^](#zoi180084t2n3){ref-type="table-fn"}   978 (86.5)
  Rural                                                 244 (19.6)          113 (46.3)[^e^](#zoi180084t2n5){ref-type="table-fn"}    19 (7.8)                                               26 (10.7)                                               233 (95.5)[^e^](#zoi180084t2n5){ref-type="table-fn"}    187 (86.2)                                                                                                                              
  Urban                                                 1003 (80.4)         360 (35.9)                                              127 (12.7)[^d^](#zoi180084t2n4){ref-type="table-fn"}   158 (15.8)[^d^](#zoi180084t2n4){ref-type="table-fn"}    901 (89.8)                                              791 (86.5)                                                                                                                              
  **Colorectal, Advanced**                                                                                                                                                                                                                                                                                                                                                                                                                         
  Overall                                               1431 (100)          594 (41.5)                                              566 (39.6)                                             189 (13.2)                                              Performance status = 2                                  143 (10.0)    NA                          NA                                                                                            
  Rural                                                 286 (20.0)          115 (40.2)                                              103 (36.0)                                             24 (8.4)                                                28 (9.8)                                                                                                                                                                                        
  Urban                                                 1145 (80.0)         479 (41.8)                                              463 (40.4)                                             165 (14.4)[^e^](#zoi180084t2n5){ref-type="table-fn"}    115 (10.0)                                                                                                                                                                                      
  **Gastric, Adjuvant**                                                                                                                                                                                                                                                                                                                                                                                                                            
  Overall                                               488 (100)           164 (33.6)                                              137 (28.1)                                             84 (17.2)                                               Stage T3-T4                                             328 (67.2)    ≥4 Nodes                    205 (42.0)    NA                                                                              
  Rural                                                 83 (17.0)           34 (41.0)                                               16 (19.3)                                              7 (8.4)                                                 60 (72.3)                                               41 (49.4)                                                                                                                               
  Urban                                                 405 (83.0)          130 (32.1)                                              121 (29.9)                                             77 (19.0)[^d^](#zoi180084t2n4){ref-type="table-fn"}     268 (66.2)                                              164 (40.5)                                                                                                                              
  **Colorectal, Adjuvant**                                                                                                                                                                                                                                                                                                                                                                                                                         
  Overall                                               2593 (100)          988 (38.1)                                              1050 (40.5)                                            182 (7.0)                                               Performance status = 2                                  75 (2.9)      2-3 Nodes                   803 (31.0)    Stage T3-T4                                                                     2212 (85.3)
  Rural                                                 605 (23.3)          234 (38.7)                                              253 (41.8)                                             9 (1.5)                                                 14 (2.3)                                                187 (30.9)    520 (86.0)                                                                                                                
  Urban                                                 1988 (76.7)         754 (37.9)                                              797 (40.1)                                             173 (8.7)[^e^](#zoi180084t2n5){ref-type="table-fn"}     61 (3.1)                                                616 (31.0)    1692 (85.1)                                                                                                               
  **Prostate 1, Advanced**                                                                                                                                                                                                                                                                                                                                                                                                                         
  Overall                                               1333 (100)          993 (74.5)                                              NA                                                     298 (22.4)                                              Performance status ≥2                                   50 (3.8)      Severity = extensive        1057 (79.3)   NA                                                                              
  Rural                                                 304 (22.8)          230 (75.7)                                              39 (12.8)                                              10 (3.3)                                                239 (78.6)                                                                                                                                                                                      
  Urban                                                 1029 (77.2)         763 (74.1)                                              259 (25.2)[^e^](#zoi180084t2n5){ref-type="table-fn"}   40 (3.9)                                                818 (79.5)                                                                                                                                                                                      
  **Prostate 2, Advanced**                                                                                                                                                                                                                                                                                                                                                                                                                         
  Overall                                               2055 (100)          1296 (63.1)                                             NA                                                     384 (18.7)                                              Performance status ≥2                                   150 (7.3)     Severity = extensive        1470 (71.5)   NA                                                                              
  Rural                                                 320 (15.6)          201 (62.8)                                              28 (8.8)                                               22 (6.9)                                                223 (69.7)                                                                                                                                                                                      
  Urban                                                 1735 (84.4)         1095 (63.1)                                             356 (20.5)[^e^](#zoi180084t2n5){ref-type="table-fn"}   128 (7.4)                                               1247 (71.9)                                                                                                                                                                                     
  **Prostate, Advanced Hormone Refractory**                                                                                                                                                                                                                                                                                                                                                                                                        
  Overall                                               1658 (100)          1174 (70.8)                                             NA                                                     229 (13.8)                                              Performance status ≥2                                   150 (9.0)     Extraskeletal metastases    879 (53.0)    Non-PSA progression                                                             1345 (81.1)
  Rural                                                 325 (19.6)          246 (75.7)[^d^](#zoi180084t2n4){ref-type="table-fn"}    24 (7.4)                                               28 (8.6)                                                146 (44.9)                                              271 (83.4)                                                                                                                              
  Urban                                                 1333 (80.4)         928 (69.6)                                              205 (15.4)[^e^](#zoi180084t2n5){ref-type="table-fn"}   122 (9.2)                                               733 (55.0)[^e^](#zoi180084t2n5){ref-type="table-fn"}    1074 (80.6)                                                                                                                             
  **Ovarian, Advanced**                                                                                                                                                                                                                                                                                                                                                                                                                            
  Overall                                               903 (100)           247 (27.4)                                              NA                                                     27 (3.0)                                                Stage IV or suboptimal III                              109 (12.1)    NA                          NA                                                                                            
  Rural                                                 170 (18.8)          50 (29.4)                                               5 (2.9)                                                21 (12.4)                                                                                                                                                                                                                                               
  Urban                                                 733 (81.2)          197 (26.9)                                              22 (3.0)                                               88 (12.0)                                                                                                                                                                                                                                               
  **Acute Myeloid Leukemia**                                                                                                                                                                                                                                                                                                                                                                                                                       
  Overall                                               1748 (100)          341 (19.5)                                              803 (45.9)                                             155 (8.9)                                               Performance status ≥2                                   405 (23.2)    NA                          NA                                                                                            
  Rural                                                 455 (26.0)          101 (22.2)                                              216 (47.5)                                             25 (5.5)                                                112 (24.6)                                                                                                                                                                                      
  Urban                                                 1293 (74.0)         240 (18.6)                                              587 (45.4)                                             130 (10.1)[^e^](#zoi180084t2n5){ref-type="table-fn"}    293 (22.7)                                                                                                                                                                                      
  **Non--Small Cell Lung Cancer, Advanced**                                                                                                                                                                                                                                                                                                                                                                                                        
  Overall                                               1461 (100)          573 (39.2)                                              461 (31.6)                                             181 (12.4)                                              ≥5% Weight loss                                         564 (38.6)    Abnormal LDH                591 (40.5)    Stage IV                                                                        1331 (91)
  Rural                                                 304 (20.8)          129 (42.4)                                              90 (29.6)                                              20 (6.6)                                                117 (38.5)                                              119 (39.1)    272 (89)                                                                                                                  
  Urban                                                 1157 (79.2)         444 (38.4)                                              371 (32.1)                                             161 (13.9)[^e^](#zoi180084t2n5){ref-type="table-fn"}    447 (38.6)                                              472 (40.8)    1059 (92)                                                                                                                 
  **Non-Hodgkin Lymphoma, Advanced Aggressive**                                                                                                                                                                                                                                                                                                                                                                                                    
  Overall                                               1155 (100)          237 (20.5)                                              483 (41.8)                                             106 (9.2)                                               High or high-intermediate IPI                           568 (49.2)    NA                          NA                                                                                            
  Rural                                                 278 (24.1)          66 (23.7)                                               110 (39.6)                                             10 (3.6)                                                134 (48.2)                                                                                                                                                                                      
  Urban                                                 877 (75.9)          171 (19.5)                                              373 (42.5)                                             96 (10.9)[^e^](#zoi180084t2n5){ref-type="table-fn"}     434 (49.5)                                                                                                                                                                                      
  **Non-Hodgkin Lymphoma, Advanced Indolent**                                                                                                                                                                                                                                                                                                                                                                                                      
  Overall                                               1035 (100)          122 (11.8)                                              427 (41.3)                                             45 (4.3)                                                High or high-intermediate IPI                           157 (15.2)    NA                          NA                                                                                            
  Rural                                                 209 (20.2)          26 (12.4)                                               95 (45.5)                                              8 (3.8)                                                 41 (19.6)                                                                                                                                                                                       
  Urban                                                 826 (79.8)          96 (11.6)                                               332 (40.2)                                             37 (4.5)                                                116 (14.0)                                                                                                                                                                                      
  **Myeloma, Multiple**                                                                                                                                                                                                                                                                                                                                                                                                                            
  Overall                                               2493 (100)          751 (30.1)                                              1047 (42.0)                                            423 (17.0)                                              Stage III                                               1462 (58.6)   NA                          NA                                                                                            
  Rural                                                 568 (22.8)          175 (30.8)                                              243 (42.8)                                             51 (9.0)                                                343 (60.4)                                                                                                                                                                                      
  Urban                                                 1925 (77.2)         576 (29.9)                                              804 (41.8)                                             372 (19.3)[^e^](#zoi180084t2n5){ref-type="table-fn"}    1119 (58.1)                                                                                                                                                                                     
  **Gastrointestinal Stromal Tumor, Advanced**                                                                                                                                                                                                                                                                                                                                                                                                     
  Overall                                               633 (100)           287 (45.3)                                              283 (44.7)                                             71 (11.2)                                               Performance status = 3                                  19 (3.0)      Measurable disease          599 (94.6)    NA                                                                              
  Rural                                                 107 (16.9)          49 (45.8)                                               44 (41.1)                                              5 (4.7)                                                 5 (4.7)                                                 102 (95.3)                                                                                                                              
  Urban                                                 526 (83.1)          238 (45.3)                                              239 (45.4)                                             66 (12.5)[^d^](#zoi180084t2n4){ref-type="table-fn"}     14 (2.7)                                                497 (94.5)                                                                                                                              
  **Total**                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Overall                                               36 995 (100)        10 247 (27.7)                                           5381 (40.3)                                            4003 (10.8)                                             NA                                                      NA            NA                                                                                                                        
  Rural                                                 7184 (19.4)         2204 (30.7)[^e^](#zoi180084t2n5){ref-type="table-fn"}   1198 (40.4)                                            389 (5.4)                                                                                                                                                                                                                                               
  Urban                                                 29 811 (80.6)       8043 (27.0)                                             4183 (40.3)                                            3614 (12.1)[^e^](#zoi180084t2n5){ref-type="table-fn"}                                                                                                                                                                                                   

Abbreviations: ER, estrogen receptor; IPI, International Prognostic Index; LDH, lactate dehydrogenase; NA, not available; PR, progesterone receptor; PSA, prostate-specific antigen.

Percentage provided for the non-sex-specific cancers only.

Clinical prognostic factors are described in [Table 1](#zoi180084t1){ref-type="table"}. The percentage of patients having each factor's higher risk category is displayed in [Table 2](#zoi180084t2){ref-type="table"}.

Percentage of patients with nonmissing data.

Statistically significantly higher, *P* \< .05.

Statistically significantly higher, *P* \< .01.

Survival Outcomes {#H2-5-ZOI180084}
-----------------

The median follow-up time among patients still alive at the date of last contact for the primary analysis was the same for rural and urban patients (5.0 years each). There were few clear observed differences by residency status in OS using Kaplan-Meier curves (eFigure in the [Supplement](#note-ZOI180084-1-s){ref-type="supplementary-material"}). In patients with adjuvant-stage estrogen receptor--negative, progesterone receptor--negative breast cancer, multivariate Cox regression results showed worse OS (hazard ratio, 1.27; 95% CI, 1.06-1.51; *P* = .008) and worse CSS (hazard ratio, 1.26; 95% CI, 1.04-1.52; *P* = .02) for patients residing in rural areas. No other statistically significant differences for any survival outcome for any of the remaining 16 disease cohorts were observed ([Figure 2](#zoi180084f2){ref-type="fig"}).

![Forest Plot Showing the Association of Rural Residence and Survival Outcomes From Cox Regression Analyses\
Results are grouped by adjuvant vs advanced disease and ordered in ascending order of the overall survival hazard ratio (HR). Each horizontal bar represents the 95% confidence interval for the associated HR (box). Hazard ratios to the left of the line of equal hazard indicate better survival for rural patients, and HRs to the right of line of equal hazard indicate worse survival for rural patients. ER indicates estrogen receptor; PR, progesterone receptor.](jamanetwopen-1-e181235-g002){#zoi180084f2}

Variable Cut Point Analyses {#H2-6-ZOI180084}
---------------------------

[Figure 3](#zoi180084f3){ref-type="fig"} shows the results of the variable cut point analyses. Negative *z*scores reflect better outcomes for rural patients; positive *z*scores reflect worse outcomes for rural patients. The division of the RUCCs into urban (1) vs rural (2-9) maximized the association between residence and OS across the panel of 17 cancer cohorts. This categorization is problematic, however, because defining codes 2 and 3 as rural is not representative and results in a rural-to-urban ratio that is much different from that of the US population. The second highest average association between residence and OS occurred for rural defined as RUCCs 1 to 3 vs urban defined as RUCCs 4 to 9, reflecting the cut point specified for our primary analysis. Importantly, there was no evidence that any combination of RUCC cut point and follow-up time (1 to 10 years) resulted in a general pattern of better or worse survival for rural patients with cancer across the 17 cancer cohorts.

![Association of Rural Residency and Overall Survival for Different Cut Points of Rural-Urban Continuum Codes\
The *z*scores (each represented by a circle) reflect the strength and direction of the association of residence and overall survival for each combination of Rural-Urban Continuum Code cut point (8 different cut points) and follow-up time (1-10 years) across the panel of 17 cancer cohorts. Negative *z*scores reflect better outcomes for rural patients; positive *z*scores reflect worse outcomes for rural patients. The dark gray line connects the mean values for each cut point. The blue horizontal lines show 2-tailed critical α levels for *P* = .05 and *P* = .01 (representing an informal adjustment for multiple comparisons), and the orange horizontal lines show 2-tailed critical α levels for *P* = .006 (representing a Bonferroni adjustment for multiple \[n = 8\] comparisons).](jamanetwopen-1-e181235-g003){#zoi180084f3}

Discussion {#H1-4-ZOI180084}
==========

Numerous prior studies have documented inferior survival for rural patients with cancer.^[@zoi180084r10],[@zoi180084r15],[@zoi180084r16],[@zoi180084r17]^ However, these studies did not adequately account for differences in access to cancer care. To our knowledge, no prior study has systematically compared cancer outcomes in clinical trial participants who reside in urban vs rural settings. This comprehensive analysis examined nearly 37 000 patients with a wide variety of cancer types and cancer stages. All participants were uniformly staged, treated, and followed up under protocol-directed care in a trial setting. Although rural trial participants were older on average and less likely to identify as black than their urban counterparts, after adjustment for these factors and important clinical prognostic factors, we found no systematic pattern of differences in survival outcomes by residency status, even under varied definitions of rural residency. Thus, this study contributes to the overall evidence base about differences in survival outcomes between rural and urban patients with cancer by showing that under similar treatment conditions within a clinical trial setting, rural and urban patients having the included cancer types do in fact have similar outcomes. This finding suggests that previously observed differences in outcomes for rural and urban patients with cancer may be due, in part, to inadequate receipt of guideline-concordant cancer care (as provided in clinical trials) rather than other factors intrinsic to residing in rural areas, such as unmeasurable differences in cancer prognosis or socioeconomic status.^[@zoi180084r18]^ This conclusion is reinforced by the observation of very few differences in clinical prognostic factors between rural vs urban patients in our study.

It is more difficult to access adequate medical care for rural individuals.^[@zoi180084r3],[@zoi180084r19]^ In the United States, rural residency has emerged as an important predictor of care access in the general population of individuals with cancer.^[@zoi180084r2]^ At the same time, rural oncology resources are sparse; although 20% of the population is rural, only 3% of oncologists work in rural areas.^[@zoi180084r20]^ Rural patients with cancer are required to travel much greater distances to receive care, adding time and financial burdens to treatment. One study found that fewer than 50% of rural patients with colorectal cancer in small or isolated rural areas had access to an oncologist within 30 miles.^[@zoi180084r21]^ This travel burden can result in lower rates of standard care; rural patients with cancer were found to be about half as likely to receive breast-conserving therapy for early-stage breast cancer compared with the national average, and rates declined further as travel distance increased.^[@zoi180084r22]^ A large study of nearly 35 000 patients found that patients with stage III colon cancer who had to travel very long distances (≥250 miles) to visit an oncologist were only one-third as likely to receive adjuvant chemotherapy.^[@zoi180084r23]^ Research from Australia proposes numerous access issues that affect receipt of quality care, including delayed diagnosis due to limited access to screening or prevention tools, limited access to treating specialists, financial barriers to travel for treatment, and the physical burden of travel.^[@zoi180084r24],[@zoi180084r25],[@zoi180084r26]^ Furthermore, residents of rural areas are least likely to have private health care coverage, accentuating disparities in access to health care and prevention services.^[@zoi180084r27],[@zoi180084r28]^ Unfortunately, our study is unable to shed light on these issues given that all patients we studied were enrolled in trials.

These findings have implications for the current policy debates regarding the Affordable Care Act (ACA). Nineteen percent of patients with cancer reside in rural areas, the same as the rate of clinical trial patients from rural areas observed in this study.^[@zoi180084r1],[@zoi180084r2]^ Therefore, rural patients with cancer make up a sizeable minority of patients with cancer who may have special needs.^[@zoi180084r29]^ It is estimated that at least 22 million people will lose health care coverage if the ACA is dismantled, 14 million through loss of expanded Medicaid coverage.^[@zoi180084r30]^ In many states, rural patients benefit disproportionately from Medicaid expansion. Adequate insurance is key to ensuring access to quality care. Therefore, reducing insurance access through policy prescriptions that limit or dismantle the ACA may disproportionately impact health care access for rural patients, again further widening disparities in outcomes between rural and urban patients with cancer.

Models for improving access to quality cancer care in rural settings do exist. In Australia, the establishment of Regional Cancer Centers of Excellence are linked to major urban cancer centers to provide multidisciplinary care, improve support services, and improve clinical trial participation.^[@zoi180084r31]^ Successful centers have substantially increased the number of patients treated locally, removing a significant burden for rural patients. A shared approach between local practitioners and specialists could be a particularly useful model.^[@zoi180084r32]^ Communications facilitated through teleoncology models have been found to improve access to specialist consultations and receipt of chemotherapy closer to home.^[@zoi180084r32],[@zoi180084r33]^ In the United States, the NCI's National Community Oncology Research Program, of which SWOG is a member, is designed to bring clinical trials to community investigators and patients.^[@zoi180084r34]^ The success of this program is reflected by the results of our study, showing representative enrollment of rural patients with cancer from different regions throughout the United States ([Figure 1](#zoi180084f1){ref-type="fig"}). The Cancer Moonshot Blue Ribbon Report recommends the establishment of a large-scale patient participation network for comprehensive tumor profiling.^[@zoi180084r4]^ Patients would enroll directly in the network, an approach that could reduce barriers to access to comprehensive cancer testing and novel treatments for rural and other medically disadvantaged groups.

Limitations {#H2-7-ZOI180084}
-----------

The results of this analysis are limited by the fact that they may not represent patterns of outcomes for rural vs urban patients receiving quality care outside of a trial setting. Clinical trial participants have been shown to have better outcomes than those treated in a nontrial setting in the short term (ie, the first year after diagnosis), likely due to differences in baseline comorbid conditions.^[@zoi180084r35]^ Although this could impact the absolute estimates of survival outcomes for patients examined in this analysis, it is less likely to affect the relative rates by rural vs urban status. Moreover, a randomized comparison of rural vs urban patients and cancer survival outcomes is clearly not feasible in this setting; thus, although our regression results accounted for important demographic and clinical prognosis factors, the potential remains that unknown confounders could influence the results. For instance, rural patients who participate in clinical trials may also be more likely to have improved health behaviors,^[@zoi180084r2]^ although we found very little evidence of measurable differences between rural and urban patients in clinical risk factors ([Table 2](#zoi180084t2){ref-type="table"}). Also, travel distance may lead to trial participation barriers that differ between rural and urban patients with cancer. However, the influence of this factor for patients choosing to participate in trials (as opposed to receiving care outside of a trial) is uncertain,^[@zoi180084r36]^ especially because patients in urban areas may also choose to travel long distances for trial participation. The analysis of CSS was limited by incomplete cause-of-death information. Furthermore, we cannot presently explain why rural patients in the estrogen receptor--negative, progesterone receptor--negative, adjuvant breast cancer cohort had worse survival. One possibility is that residency is more relevant in adjuvant cancer settings, where prognosis is better overall, although we observed survival differences in only 1 of the 4 adjuvant cohorts we examined. Another possibility is that rural patients with cancer may be more likely to have delays in chemotherapy administration, which can adversely affect survival in patients with estrogen receptor--negative, progesterone receptor--negative cancers in particular.^[@zoi180084r37]^

Conclusions {#H1-5-ZOI180084}
===========

Substantial efforts to identify and mitigate disparities in access to care and outcomes based on race, ethnicity, and socioeconomic factors have received great attention.^[@zoi180084r38]^ Yet few efforts or research have focused on disparities related to geographic residency, despite the fact that the rural population in the United States represents 1 in 5 individuals. This is the largest examination of survival outcomes for rural vs urban patients with cancer receiving care in a clinical trial setting. The finding of almost no differences in outcomes by residency status across 17 different patient cohorts has potential policy implications. If rural and urban patients with cancer receiving similar care also have similar outcomes, then a reasonable inference is that the best means by which to improve outcomes for rural patients with cancer may be to improve their access to quality care. Better access to affordable health care insurance, better access to screening and prevention tools, better access to treating specialists, improved resources for traveling to receive care, and innovative new networks to give rural patients better access to new, novel treatments and clinical trials are all likely to improve outcomes for patients with cancer in rural areas. Thus multiple parallel efforts may begin to ameliorate the persistent disparity in cancer outcomes between rural and urban patients.
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**eFigure.** Kaplan-Meier Survival Curves for Rural vs Urban Patients, in Order of Descending 2-Year Overall Survival Estimates for Urban Patients
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